Please provide your email address to receive an email when new articles are posted on . CHICAGO — The voluntary withdrawal of CyPass from the global market shocked the field of ophthalmology, but the ...

A US Food and Drug Administration (FDA) safety communication was escalated to a Class I recall for Alcon’s CyPass micro-stent systems over risk of eye damage in implanted patients. The updates come in ...

Wall Street analysts are weighing in on Glaukos Corp (NASDAQ: GKOS) Wednesday after the stock jumped more than 30 percent thanks to a major competitor removing its product from the market. Alcon ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Trimming or removing the CyPass micro-stent is recommended for patients who are experiencing ...

Alcon, the eye care division of Novartis, said this week it is pulling all versions of its CyPass micro-stent from the global market based on the results of a five-year post-approval study. The ...

Sydney L. Tyson, M.D., MPH (right) lectures lectures about the CyPass Micro-Stent to ophthalmologists and optometrists at the South Jersey Society of Optometric Physicians' meeting at the SurgiCenter ...

(RTTNews) - Alcon, the eye care unit of Novartis (NVS), announced Wednesday an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. Alcon also advised surgeons to ...

Purpose: To evaluate safety and clinical outcomes of a novel supraciliary device, the CyPass Micro-Stent, for surgical treatment of open-angle glaucoma when implanted in conjunction with cataract ...

MENLO PARK, CA--(Marketwired - October 22, 2015) - Transcend Medical, Inc., a pioneer of minimally invasive glaucoma surgery (MIGS), today announced the submission to the U.S. Food and Drug ...

Shares of Glaukos Corporation (NYSE: GKOS), a mid-cap ophthalmic medical technology and pharmaceutical company, spiked by as much as 63.7% today on heavy volume. The spark? Glaukos shares are rising ...

CHICAGO — For the treatment of primary open-angle glaucoma (OAG), the CyPass Micro-Stent procedure appears safe and effective in lowering intraocular pressure (IOP) for at least 12 months, both as a ...